UnknownPhase 2

Eradication of H. Pylori Therapy Individualized by the Mutation of 23S rRNA of H. Pylori

Japan100 participantsStarted 2016-05

Plain-language summary

Patients infected with H. pylori are treated with the individualized regimen which is based on the mutation of 23S rRNA of H. pylori.

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients infected with H. pylori are invited to the study. * Patients not allergic to the any of the drugs used for eradication of H. pylori. * Patients who has agreed to participate to the study. Exclusion Criteria: * Patients allergic to the any of the drugs used for eradication of H. pylori. * Patients who do not agree to the study.

What they're measuring

Eradication rates

Timeframe: Eradication of H. pylori is measured 1 month after the therapy

Trial details

NCT IDNCT02761005

SponsorHamamatsu University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-03

Contact for this trial

TAKAHISA FURUTA, MD PHD

81-53-435-2850 tafuruta@fd6.so-net.ne.jp

View on ClinicalTrials.gov More H. Pylori Infection trials